It was a busy week in the biotech sector with lots of data readouts. This apart, the key regulatory updates and pipeline news ...

The FDA has accepted for review the BLA for mepolizumab as an add-on maintenance treatment for eosinophilic COPD.

London: GSK plc has announced that the National Medical Products Administration (NMPA) of China has accepted for review a new ...

US FDA accepts GSK’s submission for the use of Nucala to treat patients with chronic obstructive pulmonary disease: London, UK Wednesday, December 11, 2024, 10:00 Hrs [IST] GSK ...

WESTFIELD - The adage of “don’t let limitations confine you” is one that Irene Lansing embodies on a daily basis.

Mild to moderate COPD with vs without emphysema is associated with significantly worse HRQOL, but similar lung function decline.

Mepolizumab, a biologic approved for asthma, is not currently approved for COPD, but data from a 2017 study showed a trend ...

The US Food and Drug Administration (FDA) has accepted a submission from GSK to review a new indication of Nucala ...

A dipstick urine test and a mobile app may help predict disease exacerbations in COPD patients as much as a week in advance, ...

GSK plc GSK announced that the FDA has accepted its regulatory filing, seeking the approval of a new indication for Nucala ...

After previously rejecting an application for this indication, the US Food and Drug Administration (FDA) has now accepted for ...

GSK (GSK) announced the US Food and Drug Administration, FDA, has accepted for review, data from the MATINEE study to support the regulatory ...